| Literature DB >> 35798006 |
Aditya Raguram1, Samagya Banskota1, David R Liu2.
Abstract
In vivo gene editing therapies offer the potential to treat the root causes of many genetic diseases. Realizing the promise of therapeutic in vivo gene editing requires the ability to safely and efficiently deliver gene editing agents to relevant organs and tissues in vivo. Here, we review current delivery technologies that have been used to enable therapeutic in vivo gene editing, including viral vectors, lipid nanoparticles, and virus-like particles. Since no single delivery modality is likely to be appropriate for every possible application, we compare the benefits and drawbacks of each method and highlight opportunities for future improvements.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35798006 PMCID: PMC9454337 DOI: 10.1016/j.cell.2022.03.045
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850